{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:39:54Z","timestamp":1761093594865,"version":"build-2065373602"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4491,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:p>Toxic epidermal necrolysis (TEN) is a severe dermatologic disorder associated with mortality of up to 30%. Withdrawal of the causative agent is crucial in its management. Although thalidomide\u2010induced dermatologic disorders rarely were reported before thalidomide was administered to patients positive for the human immunodeficiency virus, hypersensitivity reactions including rash are the agent's major dose\u2010limiting toxicities in this population. As it is prescribed for other immunosuppressed patients, such as those with malignancies, the frequency of dermatologic reactions (including TEN) may increase. A 62\u2010year\u2010old woman developed TEN after approximately 5 weeks of thalidomide therapy for the treatment of a glioblastoma.<\/jats:p>","DOI":"10.1592\/phco.19.15.1177.30571","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T10:03:10Z","timestamp":1082973790000},"page":"1177-1180","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Thalidomide\u2010Induced Toxic Epidermal Necrolysis"],"prefix":"10.1002","volume":"19","author":[{"given":"Sandra B.","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra L.","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.1987.03390160057026","article-title":"Toxic epidermal necrolysis, a step forward in treatment","volume":"257","author":"Heimbach DM","year":"1987","journal-title":"JAMA"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/jama.1987.03390160093035","article-title":"Burn treatment for the unburned","volume":"257","author":"Pruitt BA","year":"1987","journal-title":"JAMA"},{"issue":"9","key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz J.","year":"1987","journal-title":"Arch Dermatol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/513665"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90122-X"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00023"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199207020-00004"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ajhp\/55.17.1746","article-title":"Thalidomide approval brings tight restrictions on access","volume":"55","author":"AJHP News","year":"1998","journal-title":"Am J Health-Syst Pharm"},{"volume-title":"Receives orphan drug designation from the FDA for thalidomide in brain malignancies","year":"1998","author":"Celgene. EntreMed Inc.","key":"e_1_2_1_12_2"},{"volume-title":"Reports successful interim results in cancer phase II clinical trial for thalidomide. Company press release","year":"1998","author":"Celgene. EntreMed Inc.","key":"e_1_2_1_13_2"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02197-7"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91221-F"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.1047"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(87)90006-5"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246827"},{"volume-title":"Drug evaluations [monograph on CD\u2010ROM]","year":"1998","author":"Micromedex, Inc","key":"e_1_2_1_20_2"},{"key":"e_1_2_1_21_2","first-page":"A1372","article-title":"A phase II trial of the anti\u2010angiogenic agent, thalidomide, in patients with recurrent high\u2010grade gliomas [abstr]","volume":"16","author":"Fine HA","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"volume-title":"Thalomid (thalidomide) package insert","year":"1998","author":"Celgene","key":"e_1_2_1_22_2"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-199212000-00008"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.15.1177.30571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.15.1177.30571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:10:06Z","timestamp":1761048606000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.15.1177.30571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1592\/phco.19.15.1177.30571"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.15.1177.30571","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}